Company news
Galmed Pharmaceuticals Ltd. news in 2022
Galmed Pharmaceuticals Ltd.'s news releases, calls and decks from 2022, newest first.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
December 13, 2022
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 3, 2022
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
July 6, 2022
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
May 16, 2022
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
May 1, 2022
Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
April 27, 2022
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
April 25, 2022
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
January 10, 2022
Galmed announces positive results of Phase 1 study of Amilo-5MER
January 9, 2022